Zoetis Services LLC opposed two Australian patent applications (one standard and one innovation patent application) in the name of Boehringer Ingelheim Vetmedica GmbH. The applications claim a method of treating heart failure due to asymptomatic myxomatous mitral valve disease (MMVD) in a patient (including a dog) by administering pimobendan (also known as Vetmedin®).
19 JAN 2024 | AU | March a Bumper Month for Biopharma at the Pharmaceutical Benefits Assessment Committee (PBAC) in Australia According to the Pharmaceutical Benefits Assessment...
Pearce IP is delighted to welcome Executive Lawyer & Trade Mark Attorney Kim Evans to the team. Kim leads the Pearce IP trade mark team, and joins Pearce IP from Allens...
09 FEB 2024 | AU | Biocon Biologics Enter a Five-year Exclusive Partnership with Sandoz in Australia for Trastuzumab and Bevacizumab Biosimilars On 9 February 2024, Biocon...
2 FEB 2024 | EU | US | Regeneron’s linvoseltamab MAA Filing Accepted by EMA; BLA Submitted to FDA for Multiple Myeloma Regeneron announced that its marketing authorisation...
On 24 January 2024 New Zealand introduced a new IP Bill for Geographical Indications (GIs). The bill will amend NZ law to implement aspects of the Free Trade Agreement with the...
26 JAN 2024 | SG | AbbVie to Expand Biologics Manufacturing Facility in Singapore with US$223M Investment AbbVie announced it will invest US$233M in its biologics manufacturing...
19 JAN 2024 | US | Alvotech Provides Update on FDA Facility Inspection for AVT02 and AVT04 Alvotech announced that its facility in Iceland received a form 483 from the FDA with...
The High Court of New Zealand is only rarely called on to determine applications for interlocutory injunctions in proceedings alleging patent infringement. The decision in this case was that, despite taking more than a
12 JAN 2024 | EU | Celltrion Wins European Bids for Yuflyma® (adalimumab) and Remsima® (infliximab) Korea Biomedical Review reported that Celltrion has won bids to supply...
05 JAN 2024 | AU | Celltrion’s Remsima SC®, Biobetter to Remsima®, Biosimilar to Janssen’s Remicade® (infliximab), Sales Jump 48% The Korea Biomedical Review has reported that...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
We are delighted to announce that Pearce IP’s founder and CEO Naomi Pearce has been honoured by Australasian Lawyers as one of Australia’s Most Influential Lawyers in 2023. Naomi is one of 8 lawyers awarded in the category of “Changemaker”, and is the recipient of this award for the second year in a row.
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
We are delighted to announce that Pearce IP is ranked in the Chambers and Partners Guide for 2024 in the category of Intellectual Property. Pearce IP’s Founder and CEO Naomi...
15 DEC 2023 | KR | Approval Alert: LG Chem’s Xelenka® Biosimilar to AbbVie’s Humira® (adalimumab) Approved in Korea Korea Biomed reported that LG Chem’s Xelenka®, biosimilar to...
08 DEC 2023 | US | FDA Approves First Cell-Based Gene Therapies Casgevy® and Lyfgenia® to Treat Sickle Cell Disease The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and...
Pearce IP is proud to announce that Jacinta Flattery-O’Brien PhD has again been named as one of Australia’s patent elite in the 2024 edition of IAM Global Leaders. Jacinta is...
01 DEC 2023 | US | Celltrion Files BLA for Interchangeable Prolia® (Denosumab) Biosimilar with the FDA The Korea Biomedical Review reported that Celltrion has submitted an...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
24 NOV 2023 | Celltrion Applies For EU Approval of CT-P42, Biosimilar to Regeneron’s Eylea® (aflibercept) Celltrion revealed in a corporate filing with the Repository of Korea’s...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
16 NOV 2023 | US | Approval Alert: AZ’s Truqap® (capivasertib) plus Faslodex® FDA Approved to Treat Advanced HR-positive Breast Cancer AstraZeneca (AZ) announced the FDA...
On 9 August 2023, the Registrar of Trade Marks handed down a decision in favour of Nova Pharmaceuticals Australasia Pty Ltd (Nova) regarding its GLUCO BOOST trade mark in an...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
